Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (2805)	3/19/1998 9:11:00 AM
From: Linda Kaplan	Respond to of 7041

Headline: Zonagen Announces Product Registration Filed in Mexico for Vasomax ====================================================================== THE WOODLANDS, Texas--(BW HealthWire)--March 19, 1998-- Zonagen, Inc. (NASDAQ:ZONA; Pacific: ZNG) today announced that Schering-Plough Corporation (NYSE:SGP) has filed a Product Registration Application in Mexico for Vasomax(TM) for the treatment of Male Erectile Dysfunction (MED). "The Product Registration Application in Mexico for Vasomax(TM) is an important step in the process of commercialization," said Joseph Podolski, president and chief operating officer of Zonagen. Vasomax(TM), Zonagen's immediate-release oral formulation of phentolamine mesylate, was licensed worldwide to Schering-Plough in November 1997 for the treatment of MED. Vasomax has been tested in over 300 men in Mexico and more than 3,000 men in the U.S. Zonagen, Inc. specializes in the development of products and services for the management of reproductive health. Its technologies focus on the areas of urology, female health and contraception. Through its wholly owned subsidiary, Fertility Technologies, Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN. This release may contain certain forward-looking statements, including statements regarding the clinical investigation, timing, approval and commercialization of products that involve a number of risks and uncertainties. Actual events or results may differ from the company's expectations as a result of risk factors identified in the Company's reports and registrations as filed with the U.S. Securities Exchange Commission. CONTACT: Zonagen Inc., The Woodlands Jean Anne Mire, 281/367-5892 KEYWORD: TEXAS INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY PHARMACEUTICAL Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1998, Business Wire